Study of the Combination of ACP-196 and Pembrolizumab in... | NCT02351739

Name	Class
Merck Sharp & Dohme LLC	INDUSTRY

Label	Type	Description	Intervention Names
Pembrolizumab	Other	Arm 1: pembrolizumab monotherapy	Drug: pembrolizumab
ACP-196 in combination with pembrolizumab	Other	Arm 2: ACP-196 in combination with pembrolizumab	Drug: ACP-196 in combination with pembrolizumab

Name	Type	Description	Arm Group Labels	Other Names
pembrolizumab	Drug		Pembrolizumab
ACP-196 in combination with pembrolizumab

Measure	Description	Time Frame
Number of Participants With Overall Response	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR	Every 12 weeks for up to 2 years.

Name	Affiliation	Role
Acerta Clinical Trials	1-888-292-9613; acertamc@dlss.com	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
University of Chicago		Chicago	Illinois		United States
University of Michigan

ID	Title	Description
FG000	Arm 1: Pembrolizumab Monotherapy	Arm 1: Pembrolizumab 200mg Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
FG001	Arm 2- Acalabrutinib+Pembrolizumab	Arm 2: Acalabrutinib 100mg PO BID plus Pembrolizumab 200mg administered as an intravenous (IV) infusion every 3 weeks (Q3W)

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	May 23, 2016	Jul 19, 2019

ID	Title	Description
BG000	Pembrolizumab	Arm 1: pembrolizumab monotherapy pembrolizumab
BG001	ACP-196 in Combination With Pembrolizumab	Arm 2: ACP-196 in combination with pembrolizumab ACP-196 in combination with pembrolizumab
BG002	Total	Total of all reporting groups

Units	Counts
Participants	BG00035 BG00140 BG00275

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Arm 1 - Pembrolizumab Monotherapy	Arm 1: Pembrolizumab 200mg administered as an intravenous (IV) infusion every 3 weeks (Q3W)	25	35	15	35	34	35
EG001	Arm 2 - Acalabrutinib+Pembrolizumab	Arm 2: Acalabrutinib 100mg PO BID plus Pembrolizumab 200mg administered as an intravenous (IV) infusion every 3 weeks (Q3W)	31	40	23	40	39	40

Serious Adverse Events

Term	Organ System	Assessment Type	Notes	Statistical Information
Anaemia	Blood and lymphatic system disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Coronary Artery Disease	Cardiac disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Nausea	Gastrointestinal disorders	Systematic Assessment		EG0002 affected35 at risk EG0010 affected40 at risk
Ascites	Gastrointestinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0012 affected40 at risk
Vomiting	Gastrointestinal disorders	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Autoimmune Colitis	Gastrointestinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Colitis	Gastrointestinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Diarrhea	Gastrointestinal disorders	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Duodenitis	Gastrointestinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Gastritis	Gastrointestinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Haematemesis	Gastrointestinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Impaired Gastric Emptying	Gastrointestinal disorders	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Pneumoperitoneum	Gastrointestinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Rectal Hemorrhage	Gastrointestinal disorders	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Fatigue	General disorders	Systematic Assessment	General Disorders and Administration Site Conditions	EG0001 affected35 at risk EG0011 affected40 at risk
Pyrexia	General disorders	Systematic Assessment	General Disorders and Administration Site Conditions	EG0001 affected35 at risk EG0010 affected40 at risk
Pain	General disorders	Systematic Assessment	General Disorders and Administration Site Conditions	EG0001 affected35 at risk EG0010 affected40 at risk
Autoimmune Hepatitis	Hepatobiliary disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Hepatic Failure	Hepatobiliary disorders	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Immune-Mediated Hepatitis	Hepatobiliary disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Sepsis	Infections and infestations	Systematic Assessment		EG0001 affected35 at risk EG0013 affected40 at risk
Urinary Tract Infection	Infections and infestations	Systematic Assessment		EG0002 affected35 at risk EG0012 affected40 at risk
Pneumonia	Infections and infestations	Systematic Assessment		EG0002 affected35 at risk EG0011 affected40 at risk
Cellulitis	Infections and infestations	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Clostridium Difficile Colitis	Infections and infestations	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Lower Respiratory Tract Infection	Infections and infestations	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Peritonitis Bacterial	Infections and infestations	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Systemic Candida	Infections and infestations	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Urosepsis	Infections and infestations	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Femur Fracture	Injury, poisoning and procedural complications	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Infusion Related Reaction	Injury, poisoning and procedural complications	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Radiation Proctitis	Injury, poisoning and procedural complications	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Alanine Aminotransferase Increased	Investigations	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Aspartate Aminotransferase	Investigations	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Dehydration	Metabolism and nutrition disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Failure to Thrive	Metabolism and nutrition disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Hyperglycaemia	Metabolism and nutrition disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Hyperkalaemia	Metabolism and nutrition disorders	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Hyponatraemia	Metabolism and nutrition disorders	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Arthralgia	Musculoskeletal and connective tissue disorders	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Back Pain	Musculoskeletal and connective tissue disorders	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Bone Pain	Musculoskeletal and connective tissue disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Groin Pain	Musculoskeletal and connective tissue disorders	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Malignant Neoplasm Progression	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Metastases to Liver	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Spinal Cord Compression	Nervous system disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Syncope	Nervous system disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Delirium	Psychiatric disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Acute Kidney Disease	Renal and urinary disorders	Systematic Assessment		EG0002 affected35 at risk EG0015 affected40 at risk
Haematuria	Renal and urinary disorders	Systematic Assessment		EG0001 affected35 at risk EG0012 affected40 at risk
Urinary Tract Obstruction	Renal and urinary disorders	Systematic Assessment		EG0001 affected35 at risk EG0011 affected40 at risk
Hydronephrosis	Renal and urinary disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Dyspnoea	Respiratory, thoracic and mediastinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Haemoptysis	Respiratory, thoracic and mediastinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Pneumonitis	Respiratory, thoracic and mediastinal disorders	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk
Pulmonary Alveolar Hemorrhage	Respiratory, thoracic and mediastinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Pulmonary Oedema	Respiratory, thoracic and mediastinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Respiratory Failure	Respiratory, thoracic and mediastinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0011 affected40 at risk
Deep Vein Thrombosis	Vascular disorders	Systematic Assessment		EG0001 affected35 at risk EG0010 affected40 at risk

Other Adverse Events

Term	Organ System	Assessment Type	Notes	Statistical Information
Anaemia	Blood and lymphatic system disorders	Systematic Assessment		EG0008 affected35 at risk EG00113 affected40 at risk
Tachycardia	Cardiac disorders	Systematic Assessment		EG0001 affected35 at risk EG0014 affected40 at risk
Atrial Fibrillation	Cardiac disorders	Systematic Assessment		EG0000 affected35 at risk EG0012 affected40 at risk
Sinus Tachycardia	Cardiac disorders	Systematic Assessment		EG0000 affected35 at risk EG0012 affected40 at risk
Vertigo	Ear and labyrinth disorders	Systematic Assessment		EG0002 affected35 at risk EG0010 affected40 at risk
Hypothyroidism	Endocrine disorders	Systematic Assessment		EG0006 affected35 at risk EG0013 affected40 at risk
Vision Blurred	Eye disorders	Systematic Assessment		EG0002 affected35 at risk EG0011 affected40 at risk
Vomiting	Gastrointestinal disorders	Systematic Assessment		EG00010 affected35 at risk EG00113 affected40 at risk
Diarrhea	Gastrointestinal disorders	Systematic Assessment		EG0007 affected35 at risk EG00116 affected40 at risk
Nausea	Gastrointestinal disorders	Systematic Assessment		EG00011 affected35 at risk EG00110 affected40 at risk
Constipation	Gastrointestinal disorders	Systematic Assessment		EG0005 affected35 at risk EG00112 affected40 at risk
Abdominal Pain	Gastrointestinal disorders	Systematic Assessment		EG0006 affected35 at risk EG00110 affected40 at risk
Abdominal Distension	Gastrointestinal disorders	Systematic Assessment		EG0004 affected35 at risk EG0013 affected40 at risk
Dry Mouth	Gastrointestinal disorders	Systematic Assessment		EG0003 affected35 at risk EG0013 affected40 at risk
Dysepsia	Gastrointestinal disorders	Systematic Assessment		EG0001 affected35 at risk EG0012 affected40 at risk
Dysphagia	Gastrointestinal disorders	Systematic Assessment		EG0002 affected35 at risk EG0011 affected40 at risk
Gastrooesophageal Reflux Disease	Gastrointestinal disorders	Systematic Assessment		EG0001 affected35 at risk EG0012 affected40 at risk
Proctalgia	Gastrointestinal disorders	Systematic Assessment		EG0001 affected35 at risk EG0012 affected40 at risk
Abdominal Discomfort	Gastrointestinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0012 affected40 at risk
Fatigue	General disorders	Systematic Assessment	General Disorders and Administration Site Conditions	EG00016 affected35 at risk EG00134 affected40 at risk
Pyrexia	General disorders	Systematic Assessment	General Disorders and Administration Site Conditions	EG0006 affected35 at risk EG00110 affected40 at risk
Oedema Peripheral	General disorders	Systematic Assessment	General Disorders and Administration Site Conditions	EG0004 affected35 at risk EG0017 affected40 at risk
Chills	General disorders	Systematic Assessment	General Disorders and Administration Site Conditions	EG0002 affected35 at risk EG0013 affected40 at risk
Non-Cardiac Chest pain	General disorders	Systematic Assessment	General Disorders and Administration Site Conditions	EG0001 affected35 at risk EG0014 affected40 at risk
Asthenia	General disorders	Systematic Assessment	General Disorders and Administration Site Conditions	EG0002 affected35 at risk EG0012 affected40 at risk
Gait Disturbance	General disorders	Systematic Assessment	General Disorders and Administration Site Conditions	EG0003 affected35 at risk EG0011 affected40 at risk
Peripheral Swelling	General disorders	Systematic Assessment	General Disorders and Administration Site Conditions	EG0003 affected35 at risk EG0011 affected40 at risk
Chest Pain	General disorders	Systematic Assessment	General Disorders and Administration Site Conditions	EG0001 affected35 at risk EG0012 affected40 at risk
Urinary Tract Infection	Infections and infestations	Systematic Assessment		EG0009 affected35 at risk EG0017 affected40 at risk
Candida Infection	Infections and infestations	Systematic Assessment		EG0000 affected35 at risk EG0013 affected40 at risk
Cellulitis	Infections and infestations	Systematic Assessment		EG0002 affected35 at risk EG0011 affected40 at risk
Pneumonia	Infections and infestations	Systematic Assessment		EG0002 affected35 at risk EG0011 affected40 at risk
Rhinitis	Infections and infestations	Systematic Assessment		EG0002 affected35 at risk EG0011 affected40 at risk
Upper Respiratory Tract Infection	Infections and infestations	Systematic Assessment		EG0000 affected35 at risk EG0012 affected40 at risk
Fall	Injury, poisoning and procedural complications	Systematic Assessment		EG0006 affected35 at risk EG0015 affected40 at risk
Contusion	Injury, poisoning and procedural complications	Systematic Assessment		EG0002 affected35 at risk EG0013 affected40 at risk
Infusion Related Reaction	Injury, poisoning and procedural complications	Systematic Assessment		EG0002 affected35 at risk EG0010 affected40 at risk
Alanine Aminotransferase Increased	Investigations	Systematic Assessment		EG0003 affected35 at risk EG00114 affected40 at risk
Aspartate Aminotransferase Increased	Investigations	Systematic Assessment		EG0002 affected35 at risk EG00111 affected40 at risk
Weight Decreased	Investigations	Systematic Assessment		EG0003 affected35 at risk EG0018 affected40 at risk
Blood Creatinine Increased	Investigations	Systematic Assessment		EG0005 affected35 at risk EG0015 affected40 at risk
Amylase Increased	Investigations	Systematic Assessment		EG0001 affected35 at risk EG0014 affected40 at risk
Lipase Increased	Investigations	Systematic Assessment		EG0001 affected35 at risk EG0014 affected40 at risk
Blood Alkaline Phosphatase Increased	Investigations	Systematic Assessment		EG0000 affected35 at risk EG0014 affected40 at risk
Platelet Count Decreased	Investigations	Systematic Assessment		EG0000 affected35 at risk EG0013 affected40 at risk
Decreased Appetite	Metabolism and nutrition disorders	Systematic Assessment		EG00014 affected35 at risk EG00116 affected40 at risk
Dehydration	Metabolism and nutrition disorders	Systematic Assessment		EG0001 affected35 at risk EG00110 affected40 at risk
Hypokalaemia	Metabolism and nutrition disorders	Systematic Assessment		EG0002 affected35 at risk EG0016 affected40 at risk
Hyperkalaemia	Metabolism and nutrition disorders	Systematic Assessment		EG0002 affected35 at risk EG0014 affected40 at risk
Hypophosphataemia	Metabolism and nutrition disorders	Systematic Assessment		EG0000 affected35 at risk EG0015 affected40 at risk
Hyperglycaemia	Metabolism and nutrition disorders	Systematic Assessment		EG0001 affected35 at risk EG0013 affected40 at risk
Hypomagnesaemia	Metabolism and nutrition disorders	Systematic Assessment		EG0002 affected35 at risk EG0013 affected40 at risk
Hyponatraemia	Metabolism and nutrition disorders	Systematic Assessment		EG0002 affected35 at risk EG0013 affected40 at risk
Hypocalcaemia	Metabolism and nutrition disorders	Systematic Assessment		EG0002 affected35 at risk EG0011 affected40 at risk
Acidosis	Metabolism and nutrition disorders	Systematic Assessment		EG0001 affected35 at risk EG0012 affected40 at risk
Hypercalcaemia	Metabolism and nutrition disorders	Systematic Assessment		EG0000 affected35 at risk EG0013 affected40 at risk
Hyperuricaemia	Metabolism and nutrition disorders	Systematic Assessment		EG0000 affected35 at risk EG0012 affected40 at risk
Back Pain	Musculoskeletal and connective tissue disorders	Systematic Assessment		EG0007 affected35 at risk EG0014 affected40 at risk
Arthralgia	Musculoskeletal and connective tissue disorders	Systematic Assessment		EG0006 affected35 at risk EG0013 affected40 at risk
Pain in Extremity	Musculoskeletal and connective tissue disorders	Systematic Assessment		EG0003 affected35 at risk EG0013 affected40 at risk
Muscular Weakness	Musculoskeletal and connective tissue disorders	Systematic Assessment		EG0000 affected35 at risk EG0015 affected40 at risk
Muscle Spasms	Musculoskeletal and connective tissue disorders	Systematic Assessment		EG0001 affected35 at risk EG0013 affected40 at risk
Myalgia	Musculoskeletal and connective tissue disorders	Systematic Assessment		EG0003 affected35 at risk EG0012 affected40 at risk
Bone Pain	Musculoskeletal and connective tissue disorders	Systematic Assessment		EG0002 affected35 at risk EG0012 affected40 at risk
Flank Pain	Musculoskeletal and connective tissue disorders	Systematic Assessment		EG0001 affected35 at risk EG0012 affected40 at risk
Musculoskeletal Pain	Musculoskeletal and connective tissue disorders	Systematic Assessment		EG0001 affected35 at risk EG0012 affected40 at risk
Headache	Nervous system disorders	Systematic Assessment		EG0004 affected35 at risk EG0018 affected40 at risk
Dizziness	Nervous system disorders	Systematic Assessment		EG0004 affected35 at risk EG0016 affected40 at risk
Dysgeusia	Nervous system disorders	Systematic Assessment		EG0001 affected35 at risk EG0014 affected40 at risk
Neuropathy Peripheral	Nervous system disorders	Systematic Assessment		EG0003 affected35 at risk EG0012 affected40 at risk
Paraesthesia	Nervous system disorders	Systematic Assessment		EG0002 affected35 at risk EG0012 affected40 at risk
Presyncope	Nervous system disorders	Systematic Assessment		EG0001 affected35 at risk EG0013 affected40 at risk
Balance Disorder	Nervous system disorders	Systematic Assessment		EG0000 affected35 at risk EG0012 affected40 at risk
Dizziness Postural	Nervous system disorders	Systematic Assessment		EG0000 affected35 at risk EG0012 affected40 at risk
Anxiety	Psychiatric disorders	Systematic Assessment		EG0006 affected35 at risk EG0014 affected40 at risk
Insomnia	Psychiatric disorders	Systematic Assessment		EG0002 affected35 at risk EG0017 affected40 at risk
Confusional State	Psychiatric disorders	Systematic Assessment		EG0002 affected35 at risk EG0014 affected40 at risk
Depression	Psychiatric disorders	Systematic Assessment		EG0003 affected35 at risk EG0012 affected40 at risk
Haematuria	Renal and urinary disorders	Systematic Assessment		EG0002 affected35 at risk EG0014 affected40 at risk
Dysuria	Renal and urinary disorders	Systematic Assessment		EG0004 affected35 at risk EG0011 affected40 at risk
Acute Kidney Injury	Renal and urinary disorders	Systematic Assessment		EG0002 affected35 at risk EG0012 affected40 at risk
Bladder Spasm	Renal and urinary disorders	Systematic Assessment		EG0002 affected35 at risk EG0012 affected40 at risk
Urinary Retention	Renal and urinary disorders	Systematic Assessment		EG0002 affected35 at risk EG0010 affected40 at risk
Urinary Tract Obstruction	Renal and urinary disorders	Systematic Assessment		EG0000 affected35 at risk EG0012 affected40 at risk
Dyspnoea	Respiratory, thoracic and mediastinal disorders	Systematic Assessment		EG0005 affected35 at risk EG00112 affected40 at risk
Cough	Respiratory, thoracic and mediastinal disorders	Systematic Assessment		EG0009 affected35 at risk EG0018 affected40 at risk
Haemoptysis	Respiratory, thoracic and mediastinal disorders	Systematic Assessment		EG0001 affected35 at risk EG0014 affected40 at risk
Hypoxia	Respiratory, thoracic and mediastinal disorders	Systematic Assessment		EG0002 affected35 at risk EG0013 affected40 at risk
Rhinitis Allergic	Respiratory, thoracic and mediastinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0015 affected40 at risk
Dyspnoea Exertional	Respiratory, thoracic and mediastinal disorders	Systematic Assessment		EG0001 affected35 at risk EG0012 affected40 at risk
Oropharyngeal Pain	Respiratory, thoracic and mediastinal disorders	Systematic Assessment		EG0001 affected35 at risk EG0012 affected40 at risk
Hiccups	Respiratory, thoracic and mediastinal disorders	Systematic Assessment		EG0000 affected35 at risk EG0012 affected40 at risk
Pruritus	Skin and subcutaneous tissue disorders	Systematic Assessment		EG0005 affected35 at risk EG0014 affected40 at risk
Rash	Skin and subcutaneous tissue disorders	Systematic Assessment		EG0005 affected35 at risk EG0015 affected40 at risk
Rash Maculo-Papular	Skin and subcutaneous tissue disorders	Systematic Assessment		EG0004 affected35 at risk EG0015 affected40 at risk
Dry Skin	Skin and subcutaneous tissue disorders	Systematic Assessment		EG0003 affected35 at risk EG0015 affected40 at risk
Hyperhidrosis	Skin and subcutaneous tissue disorders	Systematic Assessment		EG0004 affected35 at risk EG0013 affected40 at risk
Rash Pruritic	Skin and subcutaneous tissue disorders	Systematic Assessment		EG0001 affected35 at risk EG0012 affected40 at risk
Skin Discoloration	Skin and subcutaneous tissue disorders	Systematic Assessment		EG0002 affected35 at risk EG0010 affected40 at risk
Skin Exfoliation	Skin and subcutaneous tissue disorders	Systematic Assessment		EG0000 affected35 at risk EG0012 affected40 at risk
Hypotension	Vascular disorders	Systematic Assessment		EG0006 affected35 at risk EG0018 affected40 at risk
Hypertension	Vascular disorders	Systematic Assessment		EG0002 affected35 at risk EG0013 affected40 at risk
Joint Swelling	Musculoskeletal and connective tissue disorders	Systematic Assessment		EG0002 affected35 at risk EG0010 affected40 at risk

ID	Term
D002277	Carcinoma
D009375	Neoplasms, Glandular and Epithelial
D009370	Neoplasms by Histologic Type
D009369	Neoplasms